| Literature DB >> 35301889 |
Daniela Benedeto-Stojanov1, Milica Bjelaković1, Dragan Stojanov2, Boris Aleksovski3.
Abstract
OBJECTIVE: We aimed to identify the clinical, biochemical, and endoscopic features associated with in-hospital mortality after acute upper gastrointestinal bleeding (AUGIB), focusing on cross-validation of the Glasgow-Blatchford score (GBS), full Rockall score (RS), and Cedars-Sinai Medical Center Predictive Index (CSMCPI) scoring systems.Entities:
Keywords: Acute upper gastrointestinal bleeding; Cedars-Sinai medical center predictive index; Glasgow-Blatchford scoring system; cross-validation; full Rockall risk scoring system; in-hospital mortality risk assessment
Mesh:
Year: 2022 PMID: 35301889 PMCID: PMC8943321 DOI: 10.1177/03000605221086442
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Clinical, biochemical, and endoscopic features between survivors and non-survivors.
| Variable | Survivors | Non-survivors | p |
|---|---|---|---|
| Age, years | 67 (56–76) | 78 (64–80) | 0.008* |
| Sex | |||
| Male | 70.7% | 60.9% | 0.374 (ns) |
| Female | 29.3% | 39.1% | |
| Symptoms | 0.0003* | ||
| Both hematemesis and melena | 41.4% | 82.6% | |
| Only melena | 58.6% | 17.4% | |
| Hemodynamic stability | 1.25 × 10−23** | ||
| Stable | 50.4% | 0.0% | |
| Moderate instability | 47.4% | 17.4% | |
| State of shock | 2.3% | 82.6% | |
| Presence of comorbidities | 53.4% | 95.7% | 0.00005** |
| Liver cirrhosis | 4.5% | 21.1% | 0.0003** |
| Bleeding onset | 1.52 × 10−7** | ||
| ≥48 hours before admission | 30.8% | 0.0% | |
| <48 hours before admission | 66.9% | 69.6% | |
| In-hospital | 2.3% | 30.4% | |
| Systolic blood pressure, mmHg | 120 (100–130) | 90 (80–103) | 7.73 × 10−8** |
| Pulse, beats/minute | 85 (75–100) | 110 (100–120) | 5.25 × 10−9** |
| Blood hemoglobin, g/L | 89 (78–107) | 74 (55–93) | 0.005* |
| Serum urea, mmol/L | 12.2 (8.2–19.5) | 25.6 (15.2–30.1) | 0.00002** |
| Serum creatinine, mg/dL | 1.08 (0.89–1.43) | 1.60 (1.09–2.25) | 0.009* |
| Serum bilirubin, mg/dL | 0.64 (0.43–0.89) | 0.65 (0.49–1.39) | 0.197 (ns) |
| INR | 1.2 (1.1–1.3) | 1.6 (1.3–2.2) | 0.000001** |
| Gastric ulcers | |||
| Presence | 36.1% | 26.1% | 0.352 (ns) |
| Forrest classification | |||
| Active spurting bleed Ia | 0.0% | 0.0% | 0.999 (ns) |
| Active oozing bleed Ib | 2.3% | 4.3% | 0.558 (ns) |
| Non-bleeding visible vessel IIa | 3.8% | 4.3% | 0.892 (ns) |
| Adherent clot IIb | 7.5% | 4.3% | 0.583 (ns) |
| Dark base IIc | 13.5% | 13.0% | 0.949 (ns) |
| Lesions without active bleeding | 9.0% | 0.0% | 0.134 (ns) |
| Duodenal ulcers | |||
| Presence | 42.9% | 43.5% | 0.956 (ns) |
| Forrest Classification | |||
| Active spurting bleed Ia | 0.0% | 4.3% | 0.147 (ns) |
| Active oozing bleed Ib | 4.5% | 4.3% | 0.972 (ns) |
| Non-bleeding visible vessel IIa | 4.5% | 8.7% | 0.401 (ns) |
| Adherent clot IIb | 6.0% | 17.4% | 0.059 (ns) |
| Dark base IIc | 18.8% | 8.7% | 0.237 (ns) |
| Lesions without active bleeding | 9.0% | 0.0% | 0.134 (ns) |
| Presence of gastric erosions | 12.0% | 0.0% | 0.079 (ns) |
| Presence of duodenal erosions | 6.0% | 0.0% | 0.605 (ns) |
| Presence of Mallory–Weiss tear | 7.5% | 8.7% | 0.691 (ns) |
| Presence of esophagitis | 8.3% | 4.3% | 0.514 (ns) |
| Presence of large esophageal varices | 3.8% | 26.1% | 0.0001** |
| Tumors | 0.950 (ns) | ||
| Absent | 94.0% | 95.7% | |
| Malignant esophageal tumor | 0.8% | 0.0% | |
| Malignant gastric tumor | 4.5% | 4.3% | |
| Gastric leiomyoma | 0.8% | 0.0% | |
| Persistent GI bleeding | 1.5% | 56.5% | 3.37 × 10−11** |
| Recurrent bleeding | 5.3% | 13.0% | 0.167 (ns) |
| Intervention | |||
| Endoscopic hemostasis | 36.8% | 47.8% | 0.284 (ns) |
| Surgical intervention | 6.0% | 5.1% | 0.227 (ns) |
Categorical variables are expressed as percentage of patients and were calculated with the χ2 test. Continuous variables are expressed as median (interquartile range, Q1–Q3) and were compared with the Mann–Whitney U-test.
ns, not significant; INR, international normalized ratio; GI, gastrointestinal.
*p < 0.05, **p < 0.001.
Figure 1.Scores between survivors and non-survivors. All three scoring systems (GBS, full RS, and CSMCPI) showed significantly higher values for non-survivors than survivors. A precise separation of the values for all three analyzed scoring systems in relation to the outcomes was observed from the generated histograms.
**p < 0.001; GBS, Glasgow-Blatchford score; full RS, full Rockall score; CSMCPI , Cedars-Sinai Medical Center Predictive Index.
Figure 2.Bivariate statistical analyses between the values of the analyzed scoring systems. A linear trend of the relationship is represented, with shaded ellipses corresponding to the 95% confidence intervals for the two different outcomes (blue, survivors; red, non-survivors). The finest separation of the outcomes can be judged on the basis of the full RS and CSMCPI.
GBS, Glasgow-Blatchford score; full RS, full Rockall score; CSMCPI, Cedars-Sinai Medical Center Predictive Index.
Figure 3.Receiver operating characteristic curve analyses for assessment of the optimal cutoff points for discrimination between survivors and non-survivors.
GBS, Glasgow Blatchford score; full RS, full Rockall score; CSMCPI, Cedars-Sinai Medical Center Predictive Index.
Comparison of sensitivity, specificity, PPV, NPV, LR+, LR−, and DOR for prediction of mortality in patients with AUGIB among the scoring systems.
| Scoring system | Sensitivity | Specificity | PPV | NPV | Likelihood ratio | DOR (LR+/LR−) | False positives(type I error) | False negatives (type II error) | |
|---|---|---|---|---|---|---|---|---|---|
| LR+ | LR− | ||||||||
| GBS (>13.5) | 95.7% | 82.7% | 48.9% | 99.1% | 5.53 | 0.05 | 110.6 | 17.3% | 4.3% |
| Full RS (>6.5) | 100% | 84.2% | 53.2% | 100% | 6.33 | 0.0 | ∞ | 15.8% | 0.0% |
| CSMCPI (>5.5) | 100% | 96.2% | 81.2% | 100% | 26.3 | 0.0 | ∞ | 3.8% | 0.0% |
AUGIB, acute upper gastrointestinal bleeding; GBS, Glasgow-Blatchford score; Full RS, full Rockall score; CSMCPI, Cedars-Sinai Medical Center Predictive Index; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio.
Univariate logistic regression and ORs for mortality risk assessment after AUGIB.
| Variables | OR | 95% CI for OR | p | |
|---|---|---|---|---|
| Lower | Upper | |||
| Age, years | 1.051 | 1.010 | 1.094 | 0.014 |
| Presence of both hematemesis and melena as symptoms | 6.736 | 2.172 | 20.897 | 0.001 |
| Systolic blood pressure, mmHg | 0.935 | 0.908 | 0.962 | <0.001 |
| Pulse, beats/minute | 1.079 | 1.046 | 1.113 | <0.001 |
| Moderate hemodynamic instability | 0.234 | 0.076 | 0.725 | 0.012 |
| Hemodynamic instability – state of shock | 205.833 | 42.718 | 991.790 | <0.001 |
| Presence of comorbidities | 19.211 | 2.516 | 146.681 | 0.004 |
| Diagnosed ischemic heart disease | 16.068 | 4.514 | 57.195 | <0.001 |
| Diagnosed heart failure | 12.794 | 4.718 | 34.697 | <0.001 |
| Diagnosed liver failure | 7.471 | 2.163 | 25.806 | 0.001 |
| Diagnosed kidney failure | 4.533 | 1.633 | 12.588 | 0.004 |
| Diagnosed disseminated malignancy | 5.389 | 1.329 | 21.862 | 0.018 |
| In-hospital bleeding onset | 18.958 | 4.453 | 80.721 | <0.001 |
| Serum urea, mmol/L | 1.084 | 1.042 | 1.129 | <0.001 |
| Blood hemoglobin, g/L | 0.967 | 0.946 | 0.989 | 0.003 |
| INR | 3.525 | 1.654 | 7.513 | 0.001 |
| Liver cirrhosis | 7.471 | 2.163 | 25.806 | 0.001 |
| Presence of large esophageal varices | 9.035 | 2.487 | 32.829 | 0.001 |
| Persistent GI bleeding | 85.150 | 16.824 | 430.974 | <0.001 |
| GBS | 3.344 | 1.954 | 5.724 | <0.001 |
| Full RS | 30.262 | 4.016 | 228.031 | 0.001 |
| CSMCPI | 7.011 | 2.812 | 17.482 | <0.001 |
AUGIB, acute upper gastrointestinal bleeding; OR, odds ratio; CI, confidence interval; INR, international normalized ratio; GI, gastrointestinal; GBS, Glasgow-Blatchford score; Full RS, full Rockall score; CSMCPI, Cedars-Sinai Medical Center Predictive Index.
Variables marked with dark orange: OR of >80.
Variables marked with pale orange: OR of >10.
Sensitivity, specificity, PPV, NPV, LR+, LR−, and DOR of variables with highest effect and OR in univariate logistic regression.
| Variables | Sensitivity | Specificity | PPV | NPV | Likelihood ratio | DOR (LR+/LR−) | False positives (type I error) | False negatives (type II error) | |
|---|---|---|---|---|---|---|---|---|---|
| LR+ | LR− | ||||||||
| Hemodynamic instability (state of shock) | 82.6% | 97.7% | 86.4% | 97.0% | 35.9 | 0.18 | 199.4 | 2.3% | 17.4% |
| Persistent GI bleeding | 56.5% | 98.5% | 86.7% | 92.9% | 37.7 | 0.44 | 85.7 | 1.5% | 43.5% |
| Presence of comorbidities | 95.7% | 53.4% | 76.3% | 98.4% | 2.1 | 0.08 | 26.3 | 46.6% | 4.3% |
| In-hospital bleeding onset | 30.4% | 97.7% | 70.0% | 89.0% | 13.2 | 0.71 | 18.6 | 2.3% | 69.6% |
| Diagnosed ischemic heart disease | 87.0% | 70.7% | 33.9% | 96.9% | 2.9 | 0.18 | 16.1 | 29.3% | 13.0% |
| Diagnosed heart failure | 65.2% | 87.2% | 46.9% | 93.5% | 5.1 | 0.40 | 12.8 | 12.8% | 34.8% |
GI, gastrointestinal; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio; OR, odds ratio.
Multiple logistic model with significant prognostic risk factors for fatal outcome after AUGIB.
| Independent predictors | p | Odds ratio | Lower 95% CI | Upper 95% CI |
|---|---|---|---|---|
| Presence of hemodynamic instability (state of shock) | 0.026 (*) | 14.541 | 1.381 | 153.126 |
| CSMCPI | 0.002 (*) | 6.311 | 2.003 | 19.888 |
| Constant | 0.001 (*) | 0 | / | / |
AUGIB, acute upper gastrointestinal bleeding; CI, confidence interval; CSMCPI, Cedars-Sinai Medical Center Predictive Index.
*p < 0.05.